Could a simple CGM device help manage type 2 diabetes without insulin?
NCT ID NCT07422831
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether using an over-the-counter continuous glucose monitor (CGM) every 30 or 90 days can help people with type 2 diabetes who do not use insulin better manage their blood sugar. About 188 participants will wear the Dexcom Stelo device periodically over six months. Researchers will compare changes in A1C and time in range to usual care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dexcom Stelo continuous glucose monitor (device)
What this could lead to
If successful, this could show that periodic use of over-the-counter CGM helps people with type 2 diabetes manage their blood sugar without needing insulin, potentially making glucose monitoring more accessible.
What could go wrong
This is a relatively small, early-stage trial (188 participants) focused on feasibility and short-term outcomes. The device is not a treatment, and results may not apply to all people with type 2 diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Denver Anschutz Medical Campus
Aurora, Colorado, 80045, United States